Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors Authors: Jianlin Xu, Anshun Zhu, Yingqi Xu, Yidan Zhang, Yinchen Shen, Yongliang Niu, Hua Zhong, Runbo Zhong Published: 2025 ABSTRACT BackgroundThe C797S mutation is a prevalent resistance mechanism to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). Management of C797S-positive NSCLC encompasses diverse approaches, including targeted and chemotherapy-based therapies.MethodsThis analysis included 44 C797S mutant NSCLC patients, all of whom had developed resistance to third-generation EGFR TKIs and had comprehensive treatment and survival data available.ResultsIn the collective C797S + NSCLC cohort, chemotherapy-based therapies demonstrated superior progression-free survival (PFS) relative to non-chemotherapy treatments (5.5 versus 3.4 months, p = 0.014). Specific median PFS outcomes for various regimens were as follows: chemotherapy plus bevacizumab, 6.4 months; chemotherapy with both immunotherapy and bevacizumab, 6.1 months; and chemotherapy with immunotherapy, 4.2 months; chemotherapy alone, 3.8 months. Monotherapy and combinations involving anlotinib, different generations of EGFR TKIs, brigatinib with cetuximab, and immunotherapy alone ranged from 3.5 to 1.5 months. Among T790M+/C797S + cis patients, those receiving chemotherapy-based regimens experienced longer PFS compared to those treated with brigatinib and cetuximab (6.0 versus 2.9 months, p = 0.018). The T790M-/C797S + subgroup saw greater PFS benefits from EGFR TKI-based therapies compared to chemotherapy-based therapies (5.8 versus 4.8 months, p = 0.043).ConclusionsTo date, chemotherapy-based treatments remain the standard of care for C797S + NSCLC patients resistant to third-generation EGFR TKIs. However, for T790M-/C797S + patients received a third-generation EGFR TKI as first-line therapy, EGFR-TKI rechallenge, involving a combination of first and third-generation EGFR TKIs or first/second-generation TKIs, may be an optimal strategy. Background Lung cancer is one of the most common cancers worldwide and remains a leading cause of cancer-related deaths [1, 2]. EGFR gene mutations are common in non-small cell lung cancer (NSCLC), especially in Asian populations, and EGFR tyrosine kinase inhibitors (TKIs) have become standard therapy for patients with advanced NSCLC harboring activating EGFR mutations [3, 4]. Third-generation EGFR TKIs, such as osimertinib, almonertinib, furmonertinib and lazertinib have been shown to provide significant progression-free survival (PFS) benefits for patients with NSCLC after both first-line and subsequent-line TKI therapy [5–10]. Despite the initial response to TKIs, resistance eventually develops and disease progression occurs. One mechanism of acquired resistance is the C797S mutation, which has been reported in up to 26% of those with acquired resistance to third-generation TKIs [11, 12]. The C797S mutation occurs in exon 20 and is responsible for drug resistance by inserting a covalent bond between third-generation EGFR TKIs and the mutant EGFR site [13]. Since 2016, fourth-generation EGFR TKIs such as EAIO45 and BLU-945 have been developed to inhibit classical EGFR mutations, as well as T790M plus C797S mutations [14, 15]. However, only preclinical or phase I data are available for these drugs to date. Nonetheless, there is no fourth-generation EGFR TKI that has been approved for clinical use. Preclinical studies and some case series propose potential treatment strategies such as combining brigatinib with cetuximab or combining first-generation and third-generation EGFR TKIs for managing patients with EGFR-sensitizing mutations which have produced T790M-C797S post-osimertinib resistance [16]. Given the lack of currently approved targeted therapeutic strategies, chemotherapy and chemotherapy combined with immunotherapy have also been employed in this patient group. To date, optimal management of C797S-mutant NSCLC remains uncertain due to the limited data available. Therefore, in this retrospective analysis, we aimed to summarize clinical data of patients with advanced NSCLC harboring the C797S mutation in order to identify optimal strategies for this population. Methods Patients We retrospectively reviewed and collected the clinical data of NSCLC patients with the EGFR C797S mutation at the Shanghai Chest Hospital between July 2018 and December 2022. The inclusion criteria were as follows: (1) patients with stage IIIB/IV non-adenocarcinoma NSCLC; (2) patients who were positive for the EGFR C797S mutation (EGFR activating mutation/T790M+/C797S + cis, EGFR activating mutation/T790M+/C797S + trans, or EGFR activating mutation/T790M−/C797S+); and (3) patients who had acquired resistance to third-generation EGFR TKIs (osimertinib, almonertinib, furmonertinib or lazertinib). Patients who had primary C797S (had not previously received EGFR TKI therapy) and those without complete subsequent therapy and efficacy details were excluded from the analysis. The PFS was calculated from the date of treatment initiation to the date of disease progression or death from any cause. This retrospective study was approved by the Ethics Committee of Shanghai Chest Hospital (approve number: IS24099) and was performed following the Helsinki Declaration of 1964 (revised 2008). Written informed consent was waived by the Ethics Committee of Shanghai Chest Hospital due to the nature of our retrospective study with routine anonymous and de-identified information. Statistical methods For descriptive purposes, demographic and clinical data are summarized as medians with ranges for continuous variables, and categorical variables are expressed as the means of absolute and percentage numbers. Survival results are summarized as median values and two-sided 95% confidence intervals (CIs) and were analyzed using Kaplan-Meier’s technique, whereas the log-rank test was used for comparisons among subgroups. Hazard ratios (HRs) were calculated along with their corresponding 95% CIs as measurements of association. Statistical significance was defined as P < 0.05. SPSS software, version 22 (IBM, Armonk, NY, USA) was used for all statistical analyses. Results Patient characteristics We identified 52 patients harboring the EGFR C797S mutation through next-generation sequencing of tissue biopsies. One patient with primary C797S (who had not received EGFR TKIs before being confirmed with C797S) was excluded from this analysis. Seven patients discontinued their treatment at Shanghai Chest Hospital and could no longer be followed. A total of 44 patients with EGFR-activating mutations and C797S, who developed resistance to third-generation EGFR TKIs, were available for analysis. The patient identification flow chart is illustrated in Fig. 1. Fig. 1Flow diagram of patients studied depicting the study’s patient selection process Flow diagram of patients studied depicting the study’s patient selection process Of the 44 patients, 30 patients with the EGFR-activating mutation, T790M and C797S cis, were identified by next-generation sequencing, and one patient harbored the EGFR-activating mutation, T790M and C797S trans. Two patients harbored concomitant trans and cis EGFR T790M/C797S mutations. Eleven patients exhibited the EGFR-activating mutation and C797S mutation in the absence of T790M (Fig. 1). The concurrent mutation was more frequently an exon 19 deletion rather than EGFR L858R, observed in 35 out of 44 patients (79.5%) compared to 8 out of 44 patients (18.2%). Additionally, one patient exhibited a combination of G719S and S768I mutations (Table 1). The majority of EGFR C797S mutations concurrently manifested alongside a spectrum of other genetic alterations. The most frequent accompanying mutation was TP53, detected in 21 patients (47.7%), while EGFR amplification was second most common, occurring in 14 patients (31.8%). Concomitant genetic alterations were also frequently observed in CDKN2A (20.5%), CTNNB1 (13.6%), PTEN (13.6%), RB1 (9.1%), BRCA2 (9.1%), SMAD4 (6.8%), APC (6.8%), CDK6 (6.8%), ATM (6.8%), TOP2A (6.8%), and FGF3 (6.8%). A solitary case exhibited MET amplification. Table 1Demographic data of 44 patientsAll patients(n = 44)T790M+/C797S+ (n = 33)T790M-/C797S (n = 11)Median age (range)61 (36–75)62 (37–75)61 (36–68)Gender Male17 (38.6%)14 (42.4%)3 (27.3%) Female27 (61.4%)19 (57.6%)8 (72.7%)Smoking status History of smoking11 (25.0%)9 (27.3%)2 (18.2%) Never-smoker33 (75.0%)24 (72.7%)9 (81.8%)Concomitant EGFR acting mutation 19 del35 (79.5%)28 (84.8%)7 (63.6%) 21 L858R8 (18.2%)5 (15.2%)3 (27.3%) G719S + S768I1 (2.3%)0 (0.0%)1 (9.1%)Stage III1 (2.3%)1 (3.0%)0 (0.0%) IV43 (97.7%)32 (97.0%)11 (100.0%)Pathology Adeno44 (100.0%)33 (100.0%)11 (100.0%)ECOG 138 (86.4%)29 (87.9%)9 (81.8%) ≧ 26 (13.6%)4 (12.1%)2 (18.2%)EGFR TKIs before being confirmed C797S 1 st G EGFR TKI33 (75.0%)32 (97.7%)1 (9.1%) 2nd G EGFR TKI4 (9.1%)3 (9.1%)1 (9.1%) 3rd G EGFR TKI44 (100.0%)33 (100.0%)11 (100.0%)Number of prior lines of therapy 15 (11.4%)0 (0.0%)5 (45.5%) 236 (81.8%)30 (90.9%)6 (54.5%) ≧ 33 (6.8%)3 (9.1%)0 (0.0%)TKI tyrosine kinase inhibitor, ECOG Eastern Cooperative Oncology Group Table 1Demographic data of 44 patientsAll patients(n = 44)T790M+/C797S+ (n = 33)T790M-/C797S (n = 11)Median age (range)61 (36–75)62 (37–75)61 (36–68)Gender Male17 (38.6%)14 (42.4%)3 (27.3%) Female27 (61.4%)19 (57.6%)8 (72.7%)Smoking status History of smoking11 (25.0%)9 (27.3%)2 (18.2%) Never-smoker33 (75.0%)24 (72.7%)9 (81.8%)Concomitant EGFR acting mutation 19 del35 (79.5%)28 (84.8%)7 (63.6%) 21 L858R8 (18.2%)5 (15.2%)3 (27.3%) G719S + S768I1 (2.3%)0 (0.0%)1 (9.1%)Stage III1 (2.3%)1 (3.0%)0 (0.0%) IV43 (97.7%)32 (97.0%)11 (100.0%)Pathology Adeno44 (100.0%)33 (100.0%)11 (100.0%)ECOG 138 (86.4%)29 (87.9%)9 (81.8%) ≧ 26 (13.6%)4 (12.1%)2 (18.2%)EGFR TKIs before being confirmed C797S 1 st G EGFR TKI33 (75.0%)32 (97.7%)1 (9.1%) 2nd G EGFR TKI4 (9.1%)3 (9.1%)1 (9.1%) 3rd G EGFR TKI44 (100.0%)33 (100.0%)11 (100.0%)Number of prior lines of therapy 15 (11.4%)0 (0.0%)5 (45.5%) 236 (81.8%)30 (90.9%)6 (54.5%) ≧ 33 (6.8%)3 (9.1%)0 (0.0%)TKI tyrosine kinase inhibitor, ECOG Eastern Cooperative Oncology Group Demographic data of 44 patients TKI tyrosine kinase inhibitor, ECOG Eastern Cooperative Oncology Group All 44 patients included in the analysis had previously received third-generation EGFR TKI therapy before being confirmed with C797S by re-biopsy. Among the 33 patients harboring the T790M+/C797S + mutation, 32 had received first-generation EGFR TKI therapy, and 3 patients had received second-generation EGFR TKI therapy. Among the 11 T790M-/C797S + patients, 9 patients received a third-generation EGFR TKI as first-line therapy, while two patients received either a first- or second-generation EGFR TKI (one patient each) prior to receiving a third-generation TKI before re-biopsy. Demographic data for all patients are shown in Table 1. Subsequent therapies and efficacy Seven patients received chemotherapy plus immunotherapy and bevacizumab after being confirmed with the C797S mutation, while 16 and 7 patients received chemotherapy plus bevacizumab or chemotherapy plus immunotherapy, respectively (Fig. 2). A total of 14 patients received chemotherapy alone (case 3 received two chemotherapy regimens). Seven patients received brigatinib plus cetuximab treatment and 12 patients received anlotinib treatment. Eight patients received a first-generation EGFR TKI plus a third-generation EGFR TKI. Seven patients received a first-generation TKI or a second-generation TKI alone. Fig. 2Swimmer’s plots illustrating PFS of individual patient Swimmer’s plots illustrating PFS of individual patient For all patients with C797S mutations which developed after administration of a third-generation EGFR TKI, chemotherapy plus immunotherapy and bevacizumab resulted in an objective response rate (ORR) of 57.1% (4/7), followed in effectiveness by ORRs for chemotherapy plus bevacizumab (37.5%, 6/16), chemotherapy plus immunotherapy (28.6%, 2/7), 1 st/2nd generation EGFR TKIs (14.3%, 1/7), chemotherapy alone (13.3%, 2/15), 1 st + 3rd generation EGFR TKIs (12.5%, 1/8), anlotinib (8.3%, 1/12), brigatinib + cetuximab (0.0%, 0/7), and immunotherapy monotherapy (0.0%, 0/5) (Fig. 3A). The disease control rate (DCR) of chemotherapy plus immunotherapy and bevacizumab, chemotherapy plus bevacizumab, chemotherapy plus immunotherapy, 1 st/2nd generation EGFR TKIs, chemotherapy alone, 1 st + 3rd generation EGFR TKIs, anlotinib, brigatinib + cetuximab, and immunotherapy monotherapy was 85.7% (6/7), 93.8% (15/16), 71.4% (5/7), 71.4% (5/7), 53.3% (8/15), 62.5% (5/8), 66.7% (8/12), 42.9% (3/7), and 20.0% (1/5), respectively (Fig. 3B). Chemotherapy plus bevacizumab resulted in a PFS of 6.4 months (95% CI 3.7–9.1), followed by the PFS for chemotherapy plus immunotherapy and bevacizumab (6.1 months, 95% CI 5.1–7.1), chemotherapy plus immunotherapy (4.2 months, 95% CI 1.1–7.3), chemotherapy alone (3.8 months, 95% CI 0.1–7.6), anlotinib (3.5 months, 95% CI 3.3–3.7), 1 st + 3rd generation EGFR TKIs (3.5 months, 95% CI 2.8–4.2), 1 st/2nd generation EGFR TKIs (2.8 months, 95% CI 1.5–4.1), brigatinib + cetuximab (2.5 months, 95% CI 1.5–3.5), and immunotherapy monotherapy (1.5 months, 95% CI 0.0–3.0) (Fig. 4A). Among the 44 patients harboring C797S mutation, chemotherapy-based therapy exhibited a PFS advantage compared to regimens without chemotherapy (5.5 months, 95% CI 4.6–6.4 vs. 3.4 months, 95% CI 2.5–4.3; HR: 0.55, 95% CI 0.34–0.89, p = 0.014) (Fig. 4B). Fig. 3The ORR and DCR associated with various treatment strategies for patients with the C797S mutation The ORR and DCR associated with various treatment strategies for patients with the C797S mutation Fig. 4Kaplan-Meier plots demonstrating PFS among C797S mutation patients receiving different treatment strategies (A). The Kaplan-Meier plots comparing PFS between chemotherapy-based therapies and non-chemotherapy agents in patients with the C797S mutation (B) Kaplan-Meier plots demonstrating PFS among C797S mutation patients receiving different treatment strategies (A). The Kaplan-Meier plots comparing PFS between chemotherapy-based therapies and non-chemotherapy agents in patients with the C797S mutation (B) Subgroup analysis demonstrated that for EGFR-activating mutation/T790M+/C797S + cis patients, chemotherapy-based regimens could provide a longer PFS than brigatinib + cetuximab treatment (6.0 months, 95% CI 5.0–7.0 vs. 2.9 months, 95% CI 1.2–4.6; HR: 0.31, 95% CI 0.11–0.88, p = 0.018) (Fig. 5A). For two patients harboring concomitant trans and cis EGFR T790M/C797S mutations who received 1 st + 3rd generation EGFR TKI therapy, the PFS was 3.9 and 5.5 months (Fig. 2). Fig. 5The Kaplan-Meier plots comparing PFS between chemotherapy-based therapies and brigatinib + cetuximab for the T790M+/C797S + cis subgroup (A). The Kaplan-Meier plots comparing PFS between chemotherapy-based regimens and EGFR TKIs-based regimens for the T790M-/C797S + subgroup (B) The Kaplan-Meier plots comparing PFS between chemotherapy-based therapies and brigatinib + cetuximab for the T790M+/C797S + cis subgroup (A). The Kaplan-Meier plots comparing PFS between chemotherapy-based regimens and EGFR TKIs-based regimens for the T790M-/C797S + subgroup (B) For the T790M-/C797S + subgroup, treatment protocols based on EGFR TKIs, encompassing both combinations of 1 st and 3rd generation EGFR TKIs or monotherapies with 1 st/2nd generation agents, were associated with a prolonged PFS in comparison to chemotherapy-based regimens (5.8 months, 95% CI 3.7–7.9 vs. 4.8 months, 95% CI 0.0–10.1, p = 0.043) (Fig. 5B). First subsequent treatment patterns and PFS Among the 44 patients with confirmed C797S mutation upon re-biopsy, 26 patients (59.1%) were switched immediately to chemotherapy-based regimens (e.g., chemotherapy plus bevacizumab, chemotherapy alone, or chemotherapy plus bevacizumab and immunotherapy). The remaining 18 patients (40.9%) received targeted therapy-based regimens (Fig. 2). The median PFS for patients receiving chemotherapy-based regimens was 6.1 months (95% CI, 4.9–7.3), compared to 3.9 months (95% CI, 3.1–4.7) for those receiving targeted therapy-based regimens. Although there was a trend favoring the chemotherapy-based approach, the difference was not statistically significant (p = 0.206) (Fig. 6). Fig. 6Kaplan-Meier plots comparing PFS between chemotherapy-based therapies and target-based therapies as first subsequent treatment Kaplan-Meier plots comparing PFS between chemotherapy-based therapies and target-based therapies as first subsequent treatment Discussion In this study, we have summarized clinical data of patients with advanced lung adenocarcinoma harboring the C797S mutation, who had acquired resistance to third-generation EGFR TKIs. The results showed that chemotherapy-based strategies showed better PFS compared to non-chemotherapy agents for the total population. For the EGFR-activating mutation/T790M-/C797S + subgroup, EGFR TKI-based regimens (combinations of 1 st and 3rd generation EGFR TKIs or monotherapies with 1 st/2nd generation agents) resulted in longer PFS than chemotherapy-based regimens (5.8 vs. 4.8 months, p = 0.043). The current study’s ORR and PFS outcomes for monotherapy immunotherapy (0.0%, 1.5 months) align with previous findings, suggesting that immunotherapy alone may not be suitable for EGFR-mutant patients [17]. Several studies have investigated chemotherapy-based strategies for patients previously treated with EGFR TKIs, including the ORIENT-31 [18], CheckMate-722 [19] and KEYNOTE-789 trials [20]. The CheckMate-722 and KEYNOTE-789 trials observed that the addition of immunotherapy to chemotherapy did not significantly improve PFS compared to chemotherapy alone (5.6 vs. 5.4 months and 5.6 vs. 5.5 months, respectively), indicating a marginal benefit of supplementary immunotherapy in this demographic. Consistent with this, the present study found a negligible difference in PFS between chemotherapy combined with immunotherapy and chemotherapy alone (4.2 vs. 3.8 months, respectively). Similarly, the results for chemotherapy plus immunotherapy and bevacizumab, as well as chemotherapy with bevacizumab alone, were comparable (PFS: 6.1 and 6.4 months; ORR: 57.1% and 37.5%, respectively). The ORIENT-31 [18] study explored the effectiveness of sintilimab combined with IBI305 (a bevacizumab biosimilar) and chemotherapy, sintilimab plus chemotherapy, and chemotherapy alone in EGFR-mutated NSCLC patients with progression following EGFR TKI therapy, revealing median PFS rates of 7.2, 5.5, and 4.3 months, respectively. These findings suggest a potential benefit of adding bevacizumab to chemotherapy in managing EGFR-mutated NSCLC after the emergence of resistance to targeted therapies. In the current study, all individuals with T790M-positive/C797S-positive mutations had previously been treated with first- or second-generation EGFR TKIs before transitioning to third-generation therapy. Interestingly, most detected EGFR T790M mutations coexisted with C797S mutations in the cis configuration, with the two mutations present on the same allele. These observations are in alignment with prior research [21]. Previous studies demonstrated that if C797S and T790M occur on the same chromosome (cis), the efficacy of combining brigatinib with the anti-EGFR antibody cetuximab was enhanced [16]. A sub-analysis was conducted specifically on this subgroup, directly comparing the outcomes of chemotherapy-based treatments with the brigatinib plus cetuximab regimen. Our findings indicate that chemotherapy-based approaches yielded a longer PFS than the brigatinib and cetuximab combination (6.0 months vs. 2.9 months), underscoring the recommendation of chemotherapy-based regimens as the appropriate standard treatment for these patients. Notably, the present study’s PFS and ORR for the brigatinib plus cetuximab in T790M-positive/C797S-positive cis patients (PFS 2.9 months, ORR 0.0%) were less favorable than those reported previously (PFS 14 months, ORR 60.0%). This discrepancy might be explained by the small samples included in both studies (n = 5). An ongoing phase I/II trial is assessing brigatinib combined with the EGFR antibody panitumumab in NSCLC patients with C797S mutation following osimertinib progression. Wu’s research highlights that when the C797S mutation is in trans (on a separate chromosome from T790M), there remains a sensitivity to combined first and third-generation EGFR TKI therapies [22]. Among our cohort, two patients exhibited concurrent trans and cis T790M-positive/C797S-positive mutations and were administered combined first and third-generation EGFR TKI treatment. Both patients achieved stable disease, with PFS of 3.9 and 5.5 months. Additional evidence is required to validate this treatment approach definitively. In the present report, nine of the 11 T790M-/C797S + patients used the 3rd generation EGFR TKI as first-line therapy. Only two of the 11 T790M-/C797S + patients who had progressed from third-generation EGFR TKI had previously received 1 st or 2nd generation EGFR TKIs before confirming T790M-/C797S + mutations by re-biopsy. Previous research corroborates these findings, indicating an absence of acquired EGFR T790M mutations following first-line treatment with osimertinib [23]. In this population, EGFR TKI-based regimens (combinations of 1 st and 3rd generation EGFR TKIs or monotherapies with 1 st/2nd generation agents) could produce a longer PFS than chemotherapy-based regimens (5.8 vs. 4.8 months, p = 0.043). First- and second-generation EGFR TKIs do not necessitate irreversible binding to the C797 residue to inhibit EGFR activity, which may account for these results. Acquired resistance to initial third-generation EGFR TKIs in Ba/F3 models has indicated that first or second-generation EGFR-TKIs might retain effectiveness [24]. Rangachari [25] employed preclinical models to show that EGFR-mutated lung cancers, which develop resistance to osimertinib via the EGFR-C797S mutation, are responsive to first-generation TKIs. Case report also demonstrated first-generation EGFR-TKI resensitization after third-generation EGFR-TKI resistance [26]. However, the results of the promising role of first or second-generation EGFR-TKIs in T790M-/C797S + mutant patients progressing from first-line osimertinib therapy need further confirmation. The ORCHARD study (NCT03944772), dedicated to evaluating multi-drug administration in patients with advanced EGFR-mutated NSCLC whose disease has progressed from first-line therapy with osimertinib holds the potential to provide insights into this question. This study specifically focuses on the choice of the first subsequent treatment following acquired resistance to third-generation EGFR-TKIs with emergent C797S mutation, a critical clinical scenario. We observed a trend towards superior PFS when chemotherapy-based regimens were used as the first subsequent treatment compared to targeted therapy-based regimens (6.1 months vs. 3.9 months). This finding holds significant clinical implications, offering real-world evidence to guide practitioners facing the challenge of C797S-mediated resistance. Although the p-value of 0.206 did not reach statistical significance, potentially due to the limited sample size and insufficient statistical power, this consistent trend strongly suggests that standard chemotherapy combined with anti-angiogenic agents may provide more robust and reliable disease control in overcoming C797S-mediated resistance. These results underscore the critical need for more effective, novel therapeutic strategies and a deeper biological understanding to overcome C797S-mediated resistance, as current options yield suboptimal and comparable outcomes. Conclusions To date, in patients with advanced lung adenocarcinoma harboring the C797S mutation, who have acquired resistance to third generation EGFR TKIs, chemotherapy-based regimens remain the standard therapy. Combinations of chemotherapy with bevacizumab and immunotherapy or chemotherapy plus bevacizumab may be favorable options for C797S + NSCLC patients. However, for the subset of patients negative for T790M but positive for C797S, EGFR TKI-based regimens, involving a combination of first and third-generation EGFR TKIs or first/second-generation TKIs, might lead to an extended progression-free survival. The implications of these findings have the potential to guide clinicians in formulating tailored treatment strategies.